Staphylokinase and ABO Group Phenotype: New Players in Staphylococcus Aureus Implant-associated Infections Development
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02812446 |
Recruitment Status :
Completed
First Posted : June 24, 2016
Last Update Posted : June 24, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Staphylococcal Infection | Other: IAI infection Other: Staphylococcus aureus nasal carriage infection |
Study Type : | Observational |
Actual Enrollment : | 88 participants |
Observational Model: | Case-Control |
Time Perspective: | Retrospective |
Official Title: | Staphylokinase and ABO Group Phenotype: New Players in Staphylococcus Aureus Implant-associated Infections Development |
Study Start Date : | February 2012 |
Actual Primary Completion Date : | September 2012 |
Actual Study Completion Date : | December 2013 |

Group/Cohort | Intervention/treatment |
---|---|
IAI patients group
patients with Staphylococcus aureus of implant-associated infections
|
Other: IAI infection |
control group
patients with Staphylococcus aureus nasal carriage
|
Other: Staphylococcus aureus nasal carriage infection |
- biofilm production measurement in the two groups [ Time Frame: september 2012 ]
The primary aim of this study is to identify phenotypic (biofilm production) markers in two different groups of S. aureus strains isolated from patients with IAI or screened from nasal carrier in noninfected patients undergoing orthopedic surgery.
By using resazurin method, IAI and NC nasal carriage isolates were divided into three groups. Isolates were classified as strong, moderate and weak biofilm producers.
- Clonal complexes distribution [ Time Frame: september 2012 ]
The primary aim of this study is to identify genotypic markers in two different groups of S. aureus strains isolated from patients with IAI or screened from nasal carrier in noninfected patients undergoing orthopedic surgery.
IAI and NC isolates genetic background was determined in order to compare the prevalence of individual virulence factor genes. All genes provided by the Alere StaphyType DNA microarray were studied.
- IAI and NC nasal carriage isolates genetic background [ Time Frame: september 2012 ]IAI and NC isolates genetic background was determined in order to compare the prevalence of individual virulence factor genes. All genes provided by the Alere StaphyType DNA microarray were studied
- biofilm production correlation with genotype [ Time Frame: december 2013 ]quantile-quantile (QQ)-plot analysis
- Correlation between Clonal Complexes distribution , genotype and clinical parameters [ Time Frame: december 2013 ]In order to determine whether clusters of S. aureus could be associated with clinical characteristics of the patients, search of association between CCs and clinical data was performed
- Association of ABO group phenotype and IAI S. aureus genotype [ Time Frame: december 2013 ]QQ-plots analysis
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Fifty-five IAI patients were included; two of them had two different S. aureus IAI episodes. The median age was 73 years (range: 21-96 years) with 29 women (52.7%). Twenty seven percent of patients suffered from diabetes and were smokers.
Nine patients including six women were immunosuppressed with a median age of 71 years. The main diagnosis for arthroplasty was arthrosis (38%). Implants were hip prosthesis (n = 35), knee prosthesis (n = 18) and osteosynthesis (n = 4). Main local consequences of IAI were scarce alteration (n = 34) and skin fistulization (n = 22). These IAI were treated by surgical removal of all infected tissue and implant or a combination of debridement with implant retention associated to long-term antimicrobial therapy active against biofilm microorganisms. Eighteen early, nine delayed and 30 late infections occurred. Blood group phenotypes were available for 54 patients and were distributed as follows: 26 O group, 17 A group, 10 B group and one AB group.
Inclusion Criteria:
- infected patients with S. Aureus IAI infection
- noninfected patients screened for S. aureus nasal colonization at the orthopedic consultation ward
Exclusion Criteria:
- minor
Responsible Party: | Nantes University Hospital |
ClinicalTrials.gov Identifier: | NCT02812446 |
Other Study ID Numbers: |
RC15_0456 |
First Posted: | June 24, 2016 Key Record Dates |
Last Update Posted: | June 24, 2016 |
Last Verified: | June 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
biofilm staphylokinase Staphylococcus aureus microarrays |
bone binding sialoprotein bone and joint infection blood group |
Infections Communicable Diseases Staphylococcal Infections Disease Attributes |
Pathologic Processes Gram-Positive Bacterial Infections Bacterial Infections Bacterial Infections and Mycoses |